trastuzumab emtansine + paclitaxel

This is a **combination regimen** of **trastuzumab emtansine** (also known as T-DM1) and **paclitaxel**. Trastuzumab emtansine is an antibody-drug conjugate composed of the monoclonal antibody trastuzumab, which targets the HER2 receptor, covalently linked to the cytotoxic agent DM1 (a derivative of maytansine, a microtubule inhibitor). Paclitaxel is a small molecule chemotherapeutic agent that stabilizes microtubules and inhibits their depolymerization, leading to cell cycle arrest and apoptosis. This combination has been evaluated primarily in **HER2-positive advanced breast cancer**. The rationale for combining the two agents is to leverage T-DM1's targeted activity against HER2-positive tumor cells and paclitaxel's established cytotoxic mechanisms, aiming for enhanced anti-tumor activity. Clinical experience indicates that this regimen is active but associated with notable toxicity, particularly peripheral neuropathy (from paclitaxel) and thrombocytopenia or liver enzyme elevation (from T-DM1)[1].